T1	intervention 0 25	Vandetanib with docetaxel
T2	eligibility 258 305	patients with pretreated advanced breast cancer
T3	control 509 531	placebo plus docetaxel
T4	total-participants 533 543	Sixty-four
T5	intervention-participants 601 603	35
T6	control-participants 621 623	29
T7	outcome 691 708	progression event
T8	iv-bin-abs 754 756	24
T9	iv-bin-percent 758 761	69%
T10	cv-bin-abs 797 799	18
T11	cv-bin-percent 801 804	62%
T14	outcome 1014 1045	safety and tolerability profile
T12	outcome 1207 1221	well tolerated
T13	outcome 1223 1239	Clinical benefit
T15	outcome-Measure 354 382	number of progression events
